Income Statement (Annual)

HLI / Houlihan Lokey, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2014 2015 2016 2017 2018
Revenue From Contract With Customer Including Assessed Tax - - - - -
Operating Expenses
  Labor And Related Expense 414,918 475,100 461,609 582,244 636,631
  Travel And Entertainment Expense 15,113 17,928 20,955 21,707 26,445
  Lease And Rental Expense 22,386 24,253 26,459 27,094 28,560
  Depreciation And Amortization 6,040 5,508 7,499 8,853 7,905
  Communications And Information Technology 12,272 14,013 16,017 17,628 18,481
  Professional Fees 3,398 5,563 20,687 13,073 17,117
  Other Cost And Expense Operating 13,010 7,826 11,601 15,489 13,779
  Operating Expenses 489,602 552,218 567,365 690,096 748,918
Operating Income Loss 102,848 128,654 126,400 181,995 214,446
Nonoperating Income Expense 2,478 3,481 -770 -3,508 3,390
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 105,326 132,135 125,630 178,487 217,836
Income Tax Expense Benefit 43,898 52,196 55,863 70,144 45,553
Profit Loss 61,428 79,939 69,767 108,343 172,283
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
  Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent 1,271 -2,435 -3,275 -7,304 7,961
Comprehensive Income Net Of Tax 62,591 77,446 66,466 101,039 180,244
Earnings Per Share
  Earnings Per Share Basic And Diluted Other Disclosures
    Weighted Average Number Of Shares Outstanding Basic 55,050 57,134 59,045 61,100 62,494
    Weighted Average Number Of Diluted Shares Outstanding 58,125 60,135 63,476 66,579 66,324
  Earnings Per Share Basic And Diluted
    Earnings Per Share Basic 0 0 0 0 0
    Earnings Per Share Diluted 0 0 0 0 0

Peers - Investment Advice (6282)

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="

CUSIP: 441593100